Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 7/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1329169 | 0.88 | MEN1 (0.39) | C5AR1SLC22A12RAB9AFFAR4 | |
| SCHEMBL1327921 | 0.88 | C5AR1 (0.37) | C5AR1BRD4PTK2SLC22A12MAPK14 | |
| SCHEMBL1328918 | 0.87 | ALDH1A1 (0.40) | C5AR1BRD4MAPK14LRRK2 | |
| SCHEMBL2142265 | 0.86 | C5AR1 (0.41) | C5AR1SLC22A12S1PR1FFAR4 | |
| SCHEMBL1327872 | 0.85 | C5AR1 (0.39) | C5AR1SLC22A12S1PR1RAB9AFFAR4 | |
| SCHEMBL1327126 | 0.84 | MEN1 (0.43) | C5AR1RAB9ALRRK2 | |
| SCHEMBL1328282 | 0.83 | LRRK2 (0.45) | C5AR1TTKRAB9AUSP2CYP3A4 | |
| SCHEMBL1327146 | 0.83 | C5AR1 (0.42) | C5AR1 | |
| SCHEMBL1327763 | 0.83 | FFAR4 (0.41) | C5AR1CYP2D6RAB9AUSP2CYP1A2 | |
| SCHEMBL1328960 | 0.82 | LRRK2 (0.45) | RAB9ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | claimed |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885TTK 3691/4885NLRP3 202/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885TTK 3691/4885NLRP3 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.